# Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study

> **NCT07557914** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Haibo Shao** · enrollment: 32 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma
- Diabetes

## Interventions

- **DRUG:** Epalrestat
- **DRUG:** Donafenib + Tislelizumab
- **PROCEDURE:** HAIC

## Key facts

- **NCT ID:** NCT07557914
- **Lead sponsor:** Haibo Shao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2029-02
- **Final completion:** 2029-02
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07557914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07557914, "Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07557914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*